Expertise in
1
conditions

Dr. Anne B. Warwick

Hematology | Oncology
Wrnmmcb
8901 Wisconsin Ave, 
Bethesda, MD 
Expertise in
1
conditions
Wrnmmcb
8901 Wisconsin Ave, 
Bethesda, MD 

Overview

Anne Warwick is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland.

Dr. Warwick is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Wilms Tumor, Renal Cell Carcinoma (RCC), Leukemia, Nephrectomy, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 35 peer reviewed articles and participating in 17 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in WI

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Wrnmmcb
8901 Wisconsin Ave, Bethesda, MD 20889

Additional Areas of Focus

Dr. Warwick has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Procedure, Biological, Other, Radiation
Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Completed
Publish Date: June 30, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate
Study Phase: Phase 3
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Completed
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Completed
Publish Date: June 02, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
Enrollment Status: Completed
Publish Date: June 02, 2026
Intervention Type: Other, Drug
Study Drugs: Asparaginase, Bortezomib, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Sorafenib
Study Phase: Phase 3
Renal Tumors Classification, Biology, and Banking Study
Renal Tumors Classification, Biology, and Banking Study
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Other
View 9 Less Clinical Trials

35 Total Publications

Innovative Algorithm for Incidence of Leukemia and Lymphoma in the U.S. Military Health Care System.
Innovative Algorithm for Incidence of Leukemia and Lymphoma in the U.S. Military Health Care System.
Journal: Military medicine
Published: December 11, 2024
Similar Doctors
Expertise in
19
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Expertise in
19
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Referral may be required

Office

8906 Bradmoor Dr, 
Bethesda, MD 
 (1.5 miles away)
301-496-7387
Languages Spoken:
English

Brigitte Widemann is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Widemann is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Medullary Thyroid Carcinoma, and Thyroidectomy.

Expertise in
16
conditions
Dr. Sharon A. Savage
Hematology | Oncology
Expertise in
16
conditions
Dr. Sharon A. Savage
Hematology | Oncology
Referral may be required

Office

9609 Medical Center Dr, 
Bethesda, MD 
 (0.2 miles away)
240-276-7241
Languages Spoken:
English

Sharon Savage is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Savage is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Aplastic Anemia, Pure Red Cell Aplasia, Congenital Aplastic Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Expertise in
13
conditions
Dr. Blanche P. Alter
Hematology | Oncology
Expertise in
13
conditions
Dr. Blanche P. Alter
Hematology | Oncology
Referral may be required

Office

9609 Medical Center Dr Rm 6E452, 
Rockville, MD 
 (8.0 miles away)
240-276-7239
Languages Spoken:
English

Blanche Alter is a Hematologist and an Oncologist practicing medicine in Rockville, Maryland. Dr. Alter is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Aplastic Anemia, Congenital Aplastic Anemia, Fanconi Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Frequently Asked Questions about Dr. Anne B. Warwick

How do I make an appointment with Dr. Anne B. Warwick?

You can book an appointment with Dr. Anne B. Warwick by calling their office at 301-400-1663. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anne B. Warwick a top-rated expert for Wilms Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anne B. Warwick is classified as an Distinguished expert for Wilms Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anne B. Warwick specialize in?

While Dr. Anne B. Warwick is a Hematology, they have specific expertise in Wilms Tumor, Renal Cell Carcinoma (RCC), and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Anne B. Warwick participate in research or clinical trials?

Yes. Dr. Anne B. Warwick has published 35 articles and abstracts on conditions like Wilms Tumor. You can view a list of Dr. Anne B. Warwick's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anne B. Warwick accept my insurance?

Dr. Anne B. Warwick accepts most major insurance plans, including Humana. We recommend calling the office directly at 301-400-1663 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Warwick's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile